Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ipratropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.60 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipratropium SCHEMBL27974717 | 1.00 | CHRM2 (0.60) | CHRM2CHRM5MEN1CHRM4CHRM1 | |
| Ipratropium SCHEMBL2167530 | 1.00 | CHRM2 (0.60) | CHRM2CHRM5MEN1CHRM4CHRM1 | |
| Ipratropium SCHEMBL117888 | 0.99 | CHRM2 (0.60) | CHRM2CHRM5MEN1CHRM4CHRM1 | |
| Ipratropium SCHEMBL2166848 | 0.97 | CHRM2 (0.63) | CHRM2CHRM5MEN1CHRM4CHRM1 | |
| Ipratropium SCHEMBL4231044 | 0.97 | CHRM2 (0.63) | CHRM2CHRM5MEN1CHRM4CHRM1 | |
| Ipratropium SCHEMBL28250222 | 0.96 | CHRM2 (0.65) | CHRM2CHRM5MEN1CHRM4CHRM1 | |
| Ipratropium SCHEMBL28223580 | 0.96 | CHRM2 (0.64) | CHRM2CHRM5MEN1CHRM4CHRM1 | |
| Ipratropium SCHEMBL2169666 | 0.96 | CHRM2 (0.64) | CHRM2CHRM5MEN1CHRM4CHRM1 | |
| Ipratropium SCHEMBL28250221 | 0.96 | CHRM2 (0.63) | CHRM2CHRM5MEN1CHRM4CHRM1 | |
| Atropine SCHEMBL5079571 | 0.86 | MAPT (0.64) | CHRM2CHRM5MEN1CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132112-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2026-05-14 | — | — | US | disclosed |
| US-12617780-B2 | Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting | CTXT PTY LTD (AU) | 2026-05-05 | — | — | US | disclosed |
| US-12569627-B2 | Droplet device with ejector closure | PNEUMA RESPIRATORY, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12564690-B2 | Droplet device with customizable resistance | PNEUMA RESPIRATORY, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-12521498-B2 | Droplet delivery device with location control | PNEUMA RESPIRATORY, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250388601-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250375579-A1 | DROPLET DELIVERY DEVICE FOR DELIVERY OF FLUIDS TO THE PULMONARY SYSTEM AND METHODS OF USE | PNEUMA RESPIRATORY, INC. (US) | 2025-12-11 | — | — | US | disclosed |
| US-12491324-B2 | Droplet device with inertial filtering | PNEUMA RESPIRATORY, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4638460-A1 | BENZIMIDAZOLE DERIVATIVES FOR THE MODULATION OF STING | Aculeus Therapeutics Pty Ltd (AU) | 2025-10-29 | — | — | EP | disclosed |
| EP-4077318-B1 | BENZIMIDAZOLE DIMERS AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2025-10-15 | — | — | EP | disclosed |
| EP-3416711-B1 | ADHERENCE MONITOR FOR A MEDICAMENT INHALER WITH TETHERED CAP | ADHERIUM NZ LTD (NZ) | 2022-04-06 | — | — | EP | disclosed |
| US-11285284-B2 | Methods for treatment of pulmonary lung diseases with improved therapeutic efficacy and improved dose efficiency | PNEUMA RESPIRATORY, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-11285274-B2 | Methods for the systemic delivery of therapeutic agents to the pulmonary system using a droplet delivery device | PNEUMA RESPIRATORY, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-11285283-B2 | Methods for generating and delivering droplets to the pulmonary system using a droplet delivery device | PNEUMA RESPIRATORY, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-11285285-B2 | Systems and methods comprising a droplet delivery device and a breathing assist device for therapeutic treatment | PNEUMA RESPIRATORY, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| EP-3969438-A1 | OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE | Stingthera, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3969452-A1 | BENZO[B][1,8]NAPHTHYRIDINE ACETIC ACID DERIVATIVES AND METHODS OF USE | Stingthera, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| CN-114186026-A | Natural language processing method, device, equipment and storage medium | 中国建设银行股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-20220054509-A1 | METHODS OF TREATMENT FOR DISEASE FROM CORONAVIRUS EXPOSURE | ENSEMBLE GROUP HOLDINGS, LLC | 2022-02-24 | — | — | US | disclosed |
| EP-3956001-A1 | APPARATUS FOR SIMULTANEOUSLY ADMINISTERING OXYGEN, AND METERED DOSE INHALER MEDICATION BY INHALATION | Goldman, Peter (US) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388601-A1 | Compounds, Compositions and Methods | AURKC, WEE2, ERBB2 | CHRM3 2119/4885CHRM2 1517/4885CHRM5 1997/4885 |
| US-12564690-B2 | Droplet device with customizable resistance | MTREX, EXOSC4, EXOSC9 | CHRM3 31/4885CHRM2 23/4885CHRM5 29/4885 |
| US-20260132112-A1 | COMPOUNDS | STING1, IRF3, CGAS | CHRM3 81/4885CHRM2 161/4885CHRM5 275/4885 |
| US-12617780-B2 | Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting | STING1, CGAS, IRF3 | CHRM3 94/4885CHRM2 451/4885CHRM5 404/4885 |
| US-12569627-B2 | Droplet device with ejector closure | DSP, MTREX, EXOSC10 | CHRM3 1608/4885CHRM2 2157/4885CHRM5 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.